This is individual research and does not constitute investment advice.
Americans suffer from a lot of problems.
One of them is being unable to sleep.
But for every problem, there seems to be a pill that provides a “magical solution.”
Through the first nine months of the year, Merck & Co. (NYSE: MRK) reported sales of its sleep aid, Belsomra, increased 27% to $191 million.
But that’s just one in a growing list of sleeping aids. There’s also Ambien, Lunesta, Sonata and others.
There’s a rich vein to tap, as between 50 million and 70 million Americans suffer from some kind of sleep disorder. And providing a good night’s rest rakes in tens of billions of dollars for pharmaceutical companies.
But is there an alternative to these drugs on the horizon?
In today’s edition of CannaBiz Now! I talk with president of the Association of Cannabis Specialists, Dr. Jordan Tishler.
Most investors recognize the opportunity medical marijuana offers in pain management. But the reality is there’s a whole list of ailments (including insomnia) where cannabis is proving to be effective.
Dr. Tishler shares his professional insights on a wide range of both possibilities and improbabilities.
Can cannabis shrink tumors? Is it effective for treating diabetes? How about anxiety?
These are some of the questions Dr. Tishler tackles.